Month: May 2018

FSD Pharma Inc. Commences Trading on Canadian Securities Exchange

TORONTO, May 29, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE), a Canadian cannabis company focused on building the world’s largest indoor hydroponic cultivation and processing facility through its wholly owned subsidiary FV Pharma Inc. (“FV”), a Licensed Producer (“LP”) pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is

Continue Reading “FSD Pharma Inc. Commences Trading on Canadian Securities Exchange”

Mission Ready Announces Proposed Name Change

VANCOUVER, British Columbia, May 25, 2018 (GLOBE NEWSWIRE) — Mission Ready Services Inc. (“Mission Ready” or the “Company”) (TSXV:MRS) announces that the Company proposes to change its name from Mission Ready Services Inc. to Mission Ready Solutions Inc.

High Tide Closes Private Placement over $3.7 Million including Strategic Investment by FV Pharma

CALGARY, May 2, 2018 /CNW/ – High Tide Ventures Inc. (“High Tide” or the “Company”) today announced that it has completed and closed a non-brokered private placement offering (the “Offering”), pursuant to which the Company issued 3,705,000 common shares at a price of $1.00 per share for gross proceeds of $3,705,000. Among the investors participating

Continue Reading “High Tide Closes Private Placement over $3.7 Million including Strategic Investment by FV Pharma”

Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product

Canntab Therapeutics Ltd (CSE:PILL) has unveiled a major milestone –  as the firm along with partner Emblem Corp (CVE:EMC) have received Health Canada approval for research and development activities on oral sustained release formulations of Canntab’s cannabinoids product, sending shares higher.

Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the “Company”) and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary

Continue Reading “Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation”